• CoronaCoronavirus (COVID-19) Resources

    In an effort to support our members with the most updated information on COVID-19 we developed this resource page to easily access current CDC information and other resources to assist you professionally and personally.

    We will continue to update this page with more information as it becomes available and welcome your input as we navigate through this situation. As health care professionals it is our job to educate our patients and families on prevention and the what to do if someone is symptomatic.

    View resources


  • Clinical Care OptionsNew for GAPNA members: Clinical Care Options

    GAPNA has partnered with a Clinical Care Options to offer an ongoing series of free CNE programs available to GAPNA members. "Diagnosis, Classification and Treatment of Heart Failure in Older Adults" is the latest program offered.

    In this interactive Webcast, expert faculty review the challenges of managing older adults with HF, including diagnosis, staging, and developing individualized management plans.

    Find out about it!

  • GAPNA 2020 National President Deborah Dunn, EdD, MSN, GNP-BC, ACNS-BC, GS-C interviews Dr. Ron Billano Ordona, DNP, FNP-BC about providing home-based primary care during COVID 19.

    "Facing Forward: Providing Home-based Primary Care during COVID 19"

    View the Video

Lonhala Magnair

Predicting Amyloid Deposits

Blood Test May Predict Amyloid Deposits in Brain, Potentially Indicating Alzheimer’s Disease

A number of research projects are underway to develop a sensitive blood test that could help screen people for Alzheimer’s disease in a less-invasive and costly way than current imaging and biomarker tests.

Researchers recently reported an advance for their method of detecting amyloid protein in blood (Schindler et al., 2019) and are validating the method by showing an association between blood levels of amyloid and results from conventional biomarker tests for Alzheimer’s.

Using a technique called immunoprecipitation mass spectrometry, researchers developed a precise method for quantifying how much beta-amyloid 42 and beta-amyloid 40 are in a sample of blood. Previous studies have suggested the ratio of these two forms of beta-amyloid may correspond with amyloid in the brain (watch viedo below).

Next, the researchers analyzed the blood of 158 adults (average age, 66), most without dementia symptoms, using their sensitive method, and evaluated them with positron emission tomography (PET) imaging and cerebrospinal fluid tests. Results indicated the ratio of beta-amyloid 42 and beta-amyloid 40 in blood was associated with the detection of amyloid by PET scans and cerebrospinal fluid tests.

Researchers then added other factors to their statistical model to help predict which people would have amyloid deposits with PET imaging. By adding age and APOE genetic status to the blood test results, the model was significantly better at predicting which people would have amyloid detected by PET scans.

Studies are already in progress to further evaluate this method with people who have symptoms of Alzheimer’s disease. Ideally, future studies would use tissue samples from postmortem brains rather than the less-sensitive images of plaques from PET scans to assess the relationship between the ratio of beta-amyloid 42 and beta-amyloid 40 and amyloid plaques in the brain. After more development and validation, this blood test method may help researchers to quickly screen people for eligibility in Alzheimer’s studies.


  • Schindler, S.E., Bollinger, J.G., Ovod, V., Mawuenyega, K.G., Gordon, B.A., Holtzman, D.M., … Bateman, R.J. (2019). High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology, 93(17), e1647-e1659. 2019. https://doi.org/10.1212/WNL.0000000000008081